A dominant negative PPARγ mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells

Diabetologia

Volumn 46, Issue 3, 2003, Pages 365-377

  Park, Y ^a   Freedman, B D ^a   Lee, E J ^a   Park, S ^a   Jameson, J L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

3T3 L1 cells; Adenovirus; Adipogenesis; Dominant negative; PPAR ; Protein protein interaction; Thiazolidinedione

Indexed keywords

ADENOVIRUS VECTOR; INSULIN; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TRANSCRIPTION FACTOR; CELL RECEPTOR; COMPLEMENT FACTOR D; COMPLEMENT FACTOR D, MOUSE; COMPLEMENTARY DNA; HORMONE; SERINE PROTEINASE; TRIACYLGLYCEROL;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL MUTANT; CELL STRAIN 3T3; DNA BINDING; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN SENSITIVITY; MAMMAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TWO HYBRID SYSTEM; WILD TYPE; ADENOVIRUS; ADIPOSE TISSUE; ANIMAL; DOMINANT GENE; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOUSE; MUTATION; PHYSIOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

3T3 CELLS; ADENOVIRIDAE; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; COMPLEMENT FACTOR D; DNA, COMPLEMENTARY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENES, DOMINANT; HORMONES; LIGANDS; MICE; MUTATION; PLASMIDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES; TRANSCRIPTION FACTORS; TRANSFECTION; TRIGLYCERIDES;

EID: 0038642086     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1037-4     Document Type: Article

References (60)

1. Rosen ED, Spiegelman BM (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734
2. Auwerx J (1999) PPARgamma, the ultimate thrifty gene. Diabetologia 42:1033-1049
3. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14:1293-1307
4. Tontonoz P, Graves R, Budavari AI et al. (1994) Adipocyte specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα. Nucleic Acids Res 22:5628-5634
5. Juge-Aubry C, Pernin A, Favez T et al. (1997) DNA binding properties of proxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. J Biol Chem 272:25252-25259
6. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889-895
7. Westin S, Kurokawa R, Nolte RT et al. (1998) Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395:199-202
8. Nolte RT, Wisely GB, Westin S et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143
9. Lin BC, Hong SH, Krig S, Yoh SM, Privalsky ML (1997) A confirmational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release. Mol Cell Biol 17:6131-6138
10. Lavinski RM, Jepsen K, Heinzel T et al. (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920-2925
11. Zamir I, Zhang J, Lazar MA (1997) Stoichiometric and steric principles governing repression by nuclear hormone receptor. Genes Dev 11:835-846
12. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J (1999) p300 interacts with the N- and C-terminal part of PPAR gamma2 in a ligand-independent and -dependent manner respectively. J Biol Chem 274:7681-7688
13. Takahashi N, Kawada T, Yamamoto T et al.(2002) Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor gamma. J Biol Chem 277:16906-16912
14. Zhu Y, Qi C, Jain S, Rao MS, Reddy JK (1997) Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 272:25500-25506
15. Ge K, Guermah M, Yuan CX et al. (2002) Transcription coactivator TRAP220 is required for PPARgamma2-stimulated adipogenesis. Nature 417:563-567
16. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839
17. Kubota N, Terauchi Y, Miki H et al. (1999) PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609
18. Barak Y, Nelson MC, Ong ES et al. (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595
19. Rosen ED, Sarraf P, Troy AE et al. (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617
20. Rosen ED, Hsu CH, Wang X et al. (2002) C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 16:22-26
21. Mudaliar S, Henry RR (2001) New oral therapies for type 2 diabetes mellitus; The glitazones or insulin sensitizers. Annu Rev Med 52:239-257
22. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkson WO, Willson TM, Klier SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956
23. Kletzien RF, Clarke SD, Ulrich RG (1992) Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393-398
24. Sandouk T, Reda D, Hofman C (1993) Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Physiol 264:C1600-1608
25. Yamauchi T, Kamon J, Waki H et al. (2001) The mechanisms by which both heterozygous peroxisome proliferator- activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245-41254
26. Barroso I, Gurnell M, Crowly VEF et al. (1999) Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
27. Gurnell M, Wentworth JM, Agostini M et al. (2000) A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J Biol Chem 275:5754-5759
28. Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, Chatterjee VK, O'Rahilly S (2001) Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. Mol Endocrinol 15:1729-1738
29. Collingwood TN, Rajanayagam O, Adams M et al. (1997) A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators. Proc Natl Acad Sci USA 94:248-253
30. Umesono K, Murakami KK, Thompson CC, Evans RM (1991) Direct repeat as selective response elements for the thyroid hormone, retinoic acid, and vitamine D3 receptors. Cell 65:1255-1266
31. Sadowski I, Ma J, Tiezenberg S, Ptashne M (1988) Gal4-VP16 is an unusally potent transcriptional activator. Nature 335:563-564
32. Sadowski I, Ptashne M (1989) GAL4 is phosphorylated as a consequence of transcriptional activation. Nucleic Acids Res 17:7539
33. Ito M, Yu RN, Jameson JL (1998) Steroidogenic factor-1 contains a carboxy-terminal transcriptinal activation domain that interacts with steroid receptor coactivator-1. Mol Endocrinol 12:290-301
34. Ito M, Park Y, Weck J, Mayo KE, Jameson JL (2000) Synergistic activation of inhibin alpha by steroidogenic factor-1 and cyclic adenosine 3′,5′-monophosphate. Mol Endocrinol 14:66-81
35. Tagami T, Lutz W, Kumar R, Jameson JL (1998) The interaction of vitamine D receptor with nuclear receptor corepressors and coactivators. Biochem Biophys Res Commun 253:358-363
36. Lee EJ, Anderson LM, Thimmapaya B, Jameson JL (1999) Targeted expression of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J Clin Endocrinol Metab 84:786-794
37. Lee EJ, Thimmapaya B, Jameson JL (2000) Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: implications for gene therapy. Neurosurgery 46:1461-1469
38. Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD, Jameson JL (2001) Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 276:13615-13621
39. Green H, Kehinde O (1976) Spontaneous heritable changes leading increased adipose conversion in 3T3 cells. Cell 7:105-113
40. Green H, Kehinde O (1974) Sublines of mouse 3T3 cells that accumulate lipid. Cell 1:113-116
41. Wang ZJ, Jeffs B, Ito M, Achermann JC, Yu RN, Hales DB, Jameson JL (2001) Aromatase (Cyp19) expression is up-regulated by targeted disruption of Dax1. Proc Natl Acad Sci USA 98:7988-7993
42. Savador LM, Park Y, Cottom J, Maizels ET, Jones JC, Schillace RC, Carr DW, Cheung P, Allis CD, Jameson JL, Hunzicker-Dunn M (2001) Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cells. J Biol Chem 276:40146-40155
43. Tagami T, Gu WX, Peairs PT, West BL, Jameson JL (1998) A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators. Mol Endocrinol 12:1888-1902.
44. Wurtz JM, Bourguet W, Renaud JP et al. (1996) A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3:87-94
45. Zhang J, Hu X, Lazar MA (1999) A novel role for helix 12 of retinoid X receptor in regulating repression. Mol Cell Biol 19:6448-6457
46. Hu X, Lazar MA (1999) The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402:93-96
47. Nagy L, Kao HY, Chakravarti D et al. (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380
48. Perissi V, Staszewski LM, McInerney EM et al. (1999) Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13:3198-3208
49. Shao D, Lazar MA (1997) Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 272:21473-21478
50. Gerhold DL, Liu F, Jiang G et al.(2002) Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology 143:2106-2118
51. Lopez GN, Webb P, Shinsako JH, Baxter JD, Greene GL, Kushner PJ (1999) Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators. Mol Endocrinol 13:897-909
52. Jimenez-Lara AM, Aranda A (2000) Interaction of vitamin D and retinoid receptors on regulation of gene expression. Horm Res 54:301-305
53. Brun RP, Spiegelman BM (1997) PPAR gamma and the molecular control of adipogenesis. J Endocrinol 155:217-218
54. Fajas L, Schoonjans K, Gelman L et al. (1999) Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 19:5495-5503
55. Stone RL, Bernlohr DA (1990) The molecular basis for inhibition of adipose conversion of murine 3T3-L1 cells by retinoic acid. Differentiation 45:119-127
56. Hu X, Li Y, Lazar MA (2001) Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. Mol Cell Biol 21:1747-1758
57. Deeb SS, Fajas L, Nemoto M et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased recepror acitivity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
58. Kubota N, Terauchi Y, Miki H et al. (1999) PPARg mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular Cell 4:597-609
59. Miles P, Barak Y, He W, Evans RM, Olefsky JM (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-γ defiency. J Clin. Invest 105:287-292
60. Yamauchi T, Waki H, Kamon J et al.(2001) Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013